Vesugen (KED, T-38) Dosing: Reported Protocols and Major Caveats#

There is no FDA-, EMA-, MHRA-, or Health Canada-approved dose for Vesugen. The only PubMed-anchored reference dose is the 5xFAD mouse dose of 400 mcg/kg/day intraperitoneal (Khavinson V, Ilina A, Kraskovskaya N, et al., Pharmaceuticals 2021; PMID 34071923)¹. All reported human doses come from Khavinson-program Russian-language literature and community self-experimentation. Last verified June 4, 2026.

Reported Protocols#

PubMed-Anchored Reference Dose#

The only PubMed-anchored Vesugen dose is from the 5xFAD mouse Alzheimer's model (Khavinson 2021; PMID 34071923):

• Dose: 400 mcg/kg/day
• Route: intraperitoneal injection (not subcutaneous)
• Duration: from 2 to 4 months of age in the original study
• Co-administration: KED was given alongside EDR (Pinealon) for most reported endpoints

This is a mouse reference dose for a neurological endpoint, not a human vascular dose. Translation to humans is not validated.

Approximate Human-Equivalent Dose Conversion#

Using standard allometric conversion via body-surface-area scaling (the standard HED framework), the mouse 400 mcg/kg/day maps to roughly:

• ~32-35 mcg/kg/day human equivalent
• For a 70 kg adult, ~2.2-2.5 mg/day

Caveat: this conversion assumes equivalent bioavailability and absorption between species and routes, which has not been characterised for KED. The number is a pharmacological orientation only. Community practice typically uses round-mg per injection doses (see below), which exceed this allometric estimate by a substantial multiple.

Russian Clinic / Khavinson Framework (Oral)#

The Khavinson bioregulation framework historically used short oral courses of bioregulator peptides in the low-microgram-per-kilogram range, taken sublingually, in 10-20 day blocks followed by extended off-periods. The specific Vesugen dose used in clinic practice is described in Russian-language sources from the St. Petersburg Institute.

Community-Reported Subcutaneous Protocol#

Vendor packaging and self-experimenter community discussion typically describes:

• Dose: 1-2 mg per subcutaneous injection
• Frequency: daily or every other day
• Duration: 10-20 day courses
• Cycle: repeat once or twice yearly

These figures are not derived from human pharmacokinetic studies and exceed allometric extrapolation from the 5xFAD mouse dose.

Reconstitution and Handling#

Vesugen is typically supplied as a lyophilised powder. General short-peptide handling applies:

• Reconstitute with bacteriostatic 0.9% sodium chloride
• Aim for a working concentration that allows convenient measurement (e.g., 1 mg per 0.1 mL)
• Inject subcutaneously with a 28-31 gauge insulin syringe (community practice)
• Rotate injection sites between abdominal and anterior thigh subcutaneous tissue

Caveat: none of the above is product-specific. Vesugen has no FDA-recognised manufacturer, no cGMP product label, and no clinical stability data.

Storage#

• Lyophilised powder: refrigerate (2-8 C) for long-term storage; protect from light
• Reconstituted solution: refrigerate and use within 14-28 days per general short-peptide guidance
• No Vesugen-specific stability data are available in PubMed-indexed literature

Why Self-Experimentation Is Not Recommended#

• Mechanism not validated. Independent biophysical confirmation of KED-DNA binding is absent (see Vesugen research).
• PK data absent. Plasma concentrations, half-life, and tissue distribution after either oral or subcutaneous KED in humans are not reported.
• Mouse-to-human translation is uncertain. The only PubMed-anchored dose is in mice and applies to a neural endpoint, not a vascular one.
• No dose-response data. The relationship between dose and any meaningful clinical outcome is unknown.
• Adulteration risk. Research-chemical-grade material is subject to identity and purity concerns.
• Evidence-based vascular prevention exists. Hypertension control, statins where indicated, smoking cessation, and exercise have decades of randomised trial evidence.

References#

Related Reading#

• Vesugen research and evidence base
• Vesugen side-effects profile
• Vesugen risks and legal status
• Pinealon dosing (co-administered in PMID 34071923)
• Prostamax dosing
• Epitalon dosing

Footnotes#

1. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021. PMID: 34071923. DOI: 10.3390/ph14060515. ↩